ReviewStructural MRI in Huntington's disease and recommendations for its potential use in clinical trials
Highlights
► Structural MRI has the potential to assess progression in clinical trials. ► The most promising biomarkers in HD are striatal and white matter atrophy. ► Consideration of image acquisition, processing and statistical design is essential. ► Appropriate reporting of study design is vital to allow evaluation of the literature.
Introduction
Huntington's disease (HD) is an autosomal-dominantly inherited neurological condition resulting in progressive deterioration of motor, cognitive and neuropsychiatric function. HD typically affects individuals in mid-life, having a 15–20 year disease course. Individuals at risk of developing HD are able to undergo predictive genetic testing and these ‘premanifest’ individuals have provided valuable insights into the natural history of this disease. HD has a devastating effect on patients and their families and there are currently no disease-modifying therapies licensed for treatment. However, HD research is entering a critical phase where promising novel disease-specific therapies are on the horizon (Ross and Tabrizi, 2011). There is, therefore, a pressing need for biomarkers capable of monitoring disease progression and ultimately determining drug efficacy in clinical trials. To date, the most widely used clinical assessment in HD is the Unified Huntington's Disease Rating Scale (UHDRS) (Huntington Study Group, 1996). However, this scale tends to have high inter-rater variability, is subject to floor and ceiling effects and is relatively insensitive in the premanifest stages of the disease. Recently there has been great interest in developing more objective, quantitative measures that might track progression across the disease spectrum including motor, cognitive, neuropsychiatric and imaging assessments (Weir et al., 2011). PREDICT-HD (Paulsen et al., 2008) and TRACK-HD (Tabrizi et al., 2009) are two large multi-site studies that have sought to validate such tools in preparation for clinical trials, and both studies report strong effect sizes for imaging measures even in the very earliest premanifest cohorts (Aylward et al., 2011, Tabrizi et al., 2012).
In order for imaging measures to be accepted as biomarkers, it is important to establish robust methodologies that track disease progression in a clinically meaningful way and are reproducible across multiple sites with different scanner manufacturers and field strengths. There is a wide range of imaging modalities available providing information on macrostructural changes such as atrophy (e.g., structural MRI), microstructural processes such as demyelination (e.g., diffusion weighted imaging), metabolic deficits (magnetic resonance spectroscopy) and functional changes (PET and task- and resting-state functional MRI). Studies are ongoing to establish the relative merits of these approaches (for review see Georgiou-Karistianis, 2009). However, at present, structural brain imaging remains the most widely applied technique and has the greatest documentation of robust multi-site disease-related longitudinal changes from up to 15 years prior to symptom onset through to established disease (Aylward et al., 2011, Georgiou-Karistianis et al., 2013, Tabrizi et al., 2011). Although there are a number of published diffusion and functional imaging studies showing early disease-related dysfunction, we are yet to investigate the sensitivity of such measures in large scale longitudinal studies, so we limit this review to the existing structural imaging literature.
Section snippets
Challenges in current published neuroimaging studies
There have been great advances in neuroimaging techniques over the last decade, and although reproducible group differences across multiple sites and studies (e.g., TRACK-HD and PREDICT-HD) have been demonstrated robustly, there remain a number of significant challenges when comparing cross-sectional and longitudinal findings across the published literature. Two main areas relate to the reporting of sample and neuroimaging characteristics (both acquisition and image processing). The reported
Neuroimaging of the basal ganglia
The most consistently investigated and reported neuropathological characteristic of HD is a significantly progressive volumetric reduction of the striatum, the main input nucleus of the basal ganglia (see Hersh et al., 2004, Vonsattel et al., 1985). These findings have been confirmed and expanded in MRI studies, especially from PREDICT-HD (Paulsen et al., 2008, Paulsen et al., 2010), TRACK-HD (Tabrizi et al., 2009, Tabrizi et al., 2012), and IMAGE-HD (Georgiou-Karistianis et al., 2013). Volume
Neuroimaging of whole brain, CSF and cortex
Whilst early involvement of the striatum is well-documented (Aylward et al., 2004, Ciarmiello et al., 2006, Harris et al., 1999), recently evidence has emerged suggesting there is also widespread cortical involvement in the HD degenerative process. Both cross-sectional and longitudinal global measures such as whole-brain atrophy (Aylward et al., 1998, Aylward et al., 2011, Henley et al., 2009, Paulsen et al., 2010, Rosas et al., 2003, Tabrizi et al., 2012, Wild et al., 2010), grey matter loss (
Neuroimaging of white matter
Recently, there has been accumulating evidence to suggest that WM degeneration may be an important feature in the HD neurodegenerative process. Whilst some studies have failed to detect WM atrophy in early HD (Bohanna et al., 2011, Sritharan et al., 2010) or pre-HD individuals (Rosas et al., 2006), there is now considerable evidence that WM atrophy is evident in both early HD (Aylward et al., 1998, Beglinger et al., 2005, Halliday et al., 1998, Rosas et al., 2003, Tabrizi et al., 2009) and
Cingulate
Pathological studies report cell loss in the cingulate (Thu et al., 2010), yet structural studies have produced conflicting results. Cross-sectional Freesurfer analysis has suggested increased thickness in the anterior cingulate in early HD (Nopoulos et al., 2010, Rosas et al., 2008), but both cross-sectional (Henley et al., 2009, Hobbs et al., 2011, Politis et al., 2011) and longitudinal (Ruocco et al., 2008) studies have demonstrated volume reduction in similar cohorts. Cingulate atrophy
Recommendations for neuroimaging studies
From our review of neuroimaging studies in HD, we conclude that there are sufficient data to justify consideration of structural MRI metrics as potential outcome measures in future clinical trials in both pre-HD and symp-HD. Reproducible group differences (cases vs. controls) have been found in many structural MRI measures, even in individuals who are far from onset. Structural MRI measures that show the most robust longitudinal change (in comparison with age-matched controls) from our review
Future studies
Although several large-scale MRI studies have been conducted in pre-HD and symp-HD, there are still several questions that remain to be answered. Some of these questions may be best addressed though analyses that combine data from multiple studies, which will be facilitated by the availability of MRI data from, for example, in the USA federally mandated repositories of data acquired through NIH-funded studies. Specific questions that need to be addressed include:
- •
What method of image analysis is
Conclusions
Here we provide a detailed review of the structural imaging literature to date in HD, highlight discrepancies between studies, and identify possible explanations for these inconsistencies. We recommend that future neuroimaging publications provide detailed characterisation of cohorts, together with clear documentation of methodologies to facilitate comparisons and inform clinical trial design. We argue for an intensified effort to overcome various issues still outstanding as we move closer
References (83)
- et al.
Striatal volume contributes to the prediction of onset of Huntington disease in incident cases
Biological Psychiatry
(2012) - et al.
Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study
NeuroImage
(2006) A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle?
Experimental Neurology
(2009)- et al.
Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study
Neurobiology of Disease
(2013) - et al.
Regional specificity of brain atrophy in Huntington's disease
Experimental Neurology
(1998) - et al.
Defective emotion recognition in early HD is neuropsychologically and anatomically generic
Neuropsychologia
(2008) - et al.
Emotion recognition and experience in Huntington's disease: is there a differential impairment?
Psychiatry Research
(2011) - et al.
Structural MR image processing using the BRAINS2 toolbox
Computerized Medical Imaging and Graphics
(2002) - et al.
Cerebral cortex structure in prodromal Huntington disease
Neurobiology of Disease
(2010) - et al.
Brain structure in preclinical Huntington's disease
Biological Psychiatry
(2006)
Striatal and white matter predictors of estimated diagnosis for Huntington disease
Brain Research Bulletin
Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study
Journal of the Neurological Sciences
Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques
NeuroImage
Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical “disconnection”
NeuroImage
Huntington's disease: from molecular pathogenesis to clinical treatment
Lancet Neurology
Biological and clinical manifestations of huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data
Lancet Neurology
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Lancet Neurology
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
Lancet Neurology
Development of biomarkers for Huntington's disease
Lancet Neurology
Frontal lobe volume in patients with Huntington's disease
Neurology
Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons
Neurology
Basal ganglia volume and proximity to onset in preclinical Huntington's disease
Archives of Neurology
Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease
Movement Disorders
Longitudinal change in basal ganglia volume in patients with Huntington's disease
Neurology
Longitudinal change in regional brain volumes in prodromal Huntington disease
Journal of Neurology, Neurosurgery and Psychiatry
Onset and rate of striatal atrophy in preclinical Huntington disease
Neurology
Tapping linked to function and structure in premanifest and symptomatic Huntington disease
Neurology
White matter volume and cognitive dysfunction in early Huntington's disease
Cognitive and Behavioral Neurology
Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits
Brain Imaging and Behavior
Structural neuroimaging of the basal ganglia in schizophrenic patients: a review
Wiener Medizinische Wochenschrift
Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy
Journal of Clinical and Experimental Neuropsychology
When does Huntington's disease begin?
Journal of the International Neuropsychological Society
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease
Journal of Nuclear Medicine
Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study
American Journal of Neuroradiology
Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency?
Statistics in Medicine
Combining functional and structural brain magnetic resonance imaging in Huntington disease
Journal of Computer Assisted Tomography
Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease
American Journal of Neuroradiology
Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease
Brain
Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease
Annals of Neurology
Pitfalls in the use of voxel-based morphometry as a biomarker: examples from Huntington disease
American Journal of Neuroradiology
Cited by (0)
- 1
Equal first authors.